Francisco Luis Díaz Ramírez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco Luis Díaz Ramírez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aleidy Abril Rentería Osorio
Universidad del Valle de Cuernavaca
1 shared publication - Angel Isaias Pandashina Masabanda
Universidad Nacional de Chimborazo
1 shared publication - Irene Alejandra Apolo Fajardo
Universidad de Guayaquil
1 shared publication - Jose David Alvarez Rodriguez1 shared publication
- Luz Elena Prieto Garcerant
Universidad Libre Seccional Barranquilla
1 shared publication - María José Gavino Pineda
Universidad de Guayaquil
1 shared publication
Latest Publications
- 27 December 2025
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 4 (1)
Hemodynamic Impact of Vasopressor Therapy in Critically Ill Patients with Septic Shock in the Intensive Care Unit
Septic shock remains one of the leading causes of mortality among critically ill patients admitted to intensive care units worldwide. Profound vasodilation, circulatory dysfunction, and impaired tissue perfusion frequently necessitate the use of vasopressor therapy to restore hemodynamic stability and preserve organ function. This review analyzes the current evidence regarding the hemodynamic impact of vasopressor therapy in adult patients with septic shock, with particular emphasis on clinical experiences and healthcare systems across the American continent. Scientific literature from major biomedical databases was examined to evaluate the physiological effects, therapeutic efficacy, safety profiles, and clinical outcomes associated with commonly used vasoactive agents, including norepinephrine, vasopressin, epinephrine, dopamine, phenylephrine, and angiotensin II. The findings indicate that norepinephrine remains the preferred first-line vasopressor due to its favorable balance between efficacy and safety. Early vasopressor initiation was consistently associated with improved hemodynamic stabilization, reduced duration of hypotension, and enhanced tissue perfusion. Adjunctive therapies such as vasopressin and angiotensin II demonstrated potential benefits in selected patients with refractory vasodilatory shock. The review also highlights the importance of individualized blood pressure targets, integration of microcirculatory assessment, and adherence to evidence-based sepsis protocols. Furthermore, regional differences in critical care resources, medication availability, and healthcare infrastructure were identified as important factors influencing outcomes throughout the Americas. The available evidence supports the implementation of personalized vasopressor strategies combined with comprehensive critical care management to improve survival and reduce organ dysfunction in patients with septic shock.
- 27 December 2025
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 4 (1)
Hemodynamic Impact of Vasopressor Therapy in Critically Ill Patients with Septic Shock in the Intensive Care Unit
Septic shock remains one of the leading causes of mortality among critically ill patients admitted to intensive care units worldwide. Profound vasodilation, circulatory dysfunction, and impaired tissue perfusion frequently necessitate the use of vasopressor therapy to restore hemodynamic stability and preserve organ function. This review analyzes the current evidence regarding the hemodynamic impact of vasopressor therapy in adult patients with septic shock, with particular emphasis on clinical experiences and healthcare systems across the American continent. Scientific literature from major biomedical databases was examined to evaluate the physiological effects, therapeutic efficacy, safety profiles, and clinical outcomes associated with commonly used vasoactive agents, including norepinephrine, vasopressin, epinephrine, dopamine, phenylephrine, and angiotensin II. The findings indicate that norepinephrine remains the preferred first-line vasopressor due to its favorable balance between efficacy and safety. Early vasopressor initiation was consistently associated with improved hemodynamic stabilization, reduced duration of hypotension, and enhanced tissue perfusion. Adjunctive therapies such as vasopressin and angiotensin II demonstrated potential benefits in selected patients with refractory vasodilatory shock. The review also highlights the importance of individualized blood pressure targets, integration of microcirculatory assessment, and adherence to evidence-based sepsis protocols. Furthermore, regional differences in critical care resources, medication availability, and healthcare infrastructure were identified as important factors influencing outcomes throughout the Americas. The available evidence supports the implementation of personalized vasopressor strategies combined with comprehensive critical care management to improve survival and reduce organ dysfunction in patients with septic shock.
- Open Access
- 17 November 2025
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 3 (1)
Molecular Networks and Translational Advances in Renal Fibrosis: Integrating Pathways, Therapeutic Targets, and Regional Perspectives
Renal fibrosis represents the final common pathway of chronic kidney disease (CKD) and remains a major therapeutic challenge worldwide. This review integrates recent mechanistic, translational, and regional evidence to characterize the biological architecture of fibrosis and evaluate emerging therapeutic strategies. Across the literature, a consistent pattern emerges in which TGF-β/Smad3 signaling functions as the central driver of matrix accumulation, epithelial injury, and transcriptional remodeling. This pathway is reinforced by NRF2 dysregulation, oxidative stress, and lipid peroxidation, which amplify inflammatory and fibrogenic responses. Additional mechanisms—including macrophage polarization toward M2-like phenotypes, ferroptotic injury in tubular cells, and extracellular vesicle–mediated transfer of pro-fibrotic molecules—contribute to a self-reinforcing microenvironment that accelerates structural renal decline. Five conceptual figures summarize these interactions, therapeutic frequencies, stage-dependent dynamics, comparative innovation profiles, and the growing participation of Mexico, Colombia, and Ecuador in fibrosis research. Among emerging therapies, NRF2 activation demonstrates the strongest mechanistic support, while mineralocorticoid receptor antagonists remain the most clinically mature option with proven anti-inflammatory and antifibrotic effects. Smad3 and non-coding RNA modulation, exosome-based strategies, ferroptosis inhibition, macrophage reprogramming, and ion-channel targeting represent promising but still evolving approaches. A recurrent finding across publications is that effective antifibrotic therapy will likely require multi-target, stage-adapted combinations capable of modulating oxidative, immune, and transcriptional pathways concurrently. Given the high burden of CKD in Latin America, strengthening regional translational efforts and integrating molecular advances with local epidemiological contexts are essential. Overall, current evidence supports a shift toward precision, multi-modal antifibrotic interventions that address the complex biology of renal fibrosis.
- 17 November 2025
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 3 (1)
Open AccessMolecular Networks and Translational Advances in Renal Fibrosis: Integrating Pathways, Therapeutic Targets, and Regional Perspectives
Renal fibrosis represents the final common pathway of chronic kidney disease (CKD) and remains a major therapeutic challenge worldwide. This review integrates recent mechanistic, translational, and regional evidence to characterize the biological architecture of fibrosis and evaluate emerging therapeutic strategies. Across the literature, a consistent pattern emerges in which TGF-β/Smad3 signaling functions as the central driver of matrix accumulation, epithelial injury, and transcriptional remodeling. This pathway is reinforced by NRF2 dysregulation, oxidative stress, and lipid peroxidation, which amplify inflammatory and fibrogenic responses. Additional mechanisms—including macrophage polarization toward M2-like phenotypes, ferroptotic injury in tubular cells, and extracellular vesicle–mediated transfer of pro-fibrotic molecules—contribute to a self-reinforcing microenvironment that accelerates structural renal decline. Five conceptual figures summarize these interactions, therapeutic frequencies, stage-dependent dynamics, comparative innovation profiles, and the growing participation of Mexico, Colombia, and Ecuador in fibrosis research. Among emerging therapies, NRF2 activation demonstrates the strongest mechanistic support, while mineralocorticoid receptor antagonists remain the most clinically mature option with proven anti-inflammatory and antifibrotic effects. Smad3 and non-coding RNA modulation, exosome-based strategies, ferroptosis inhibition, macrophage reprogramming, and ion-channel targeting represent promising but still evolving approaches. A recurrent finding across publications is that effective antifibrotic therapy will likely require multi-target, stage-adapted combinations capable of modulating oxidative, immune, and transcriptional pathways concurrently. Given the high burden of CKD in Latin America, strengthening regional translational efforts and integrating molecular advances with local epidemiological contexts are essential. Overall, current evidence supports a shift toward precision, multi-modal antifibrotic interventions that address the complex biology of renal fibrosis.